Glofitamab plus Polatuzumab Vedotin demonstrated a high and durable response, with an overall response rate of 78.3% and a median progression-free survival of 12.3 months in heavily pretreated patients with relapsed or refractory large B-cell lymphoma. The treatment showed manageable safety with cytokine release syndrome being the most common adverse event.
Study
|
Open-label, multicenter, phase Ib/II study [NCT03533283] |
| Patients with relapsed/refractory large B-cell lymphoma |
| Glofitamab plus Polatuzumab Vedotin, n=129
|
Efficacy
|
ORR: 78.3%, CR: 59.7% |
| mPFS: 12.3 mos |
| mOS: 33.8 mos
|
Safety
|
Grade >=3 AE: neutropenia (32.6%), anemia (8.5%), thrombocytopenia (8.5%) |
| CRS: 43.4% |
| Grade 5 AEs: 9.3%, treatment discontinuations: 14.7%
|
J Clin Oncol. Published online October 20, 2025
http://doi.org/10.1200/JCO-25-00992
Reviewed by Ulas D. Bayraktar, MD on Nov 15, 2025
